InvestSMART

ReNerve Limited (ASX: RNV) - Share Price

Current share price for RNV : $0.076 0.005 (6.17%)+

ReNerve Limited (RNV), an ASX-listed company, is an Australian biotechnology company that has altered peripheral nerve surgery with its ready-to-use solutions for peripheral nerve injuries (PNI).

RNV General Information +

ASX Code RNV
Website http://www.renerve.com.au
Industry/Sector Health Care Supplies
Market Cap ($M) 10
RNV Share Price $0.076
Day High $0.076
Day Low $0.075
Last Close $0.081
RNV Share Price Movement $0.01 ( 6.17% )
Prices as at 16:40, 26 Jun 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

ReNerve Limited (RNV) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from ReNerve Limited (RNV) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

ReNerve Limited (RNV) price-sensitive announcements

RNV - ReNerve appoints J4 as second Empliq manufacturing partner
ReNerve Limited has appointed J4 as a second manufacturing partner for its Empliq™ product
ReNerve Limited (RNV)
11 Jun 2026 | 9:47 AM
RNV - ReNerve appoints distribution partner for Malaysian Market
ReNerve Limited, an Australian biotechnology company specializing in peripheral nerve inju
ReNerve Limited (RNV)
5 Jun 2026 | 9:15 AM
RNV - New distribution agreement for broader Hong Kong market
ReNerve Limited announced a new distribution agreement with Swedish Trading Company (STC)
ReNerve Limited (RNV)
1 Jun 2026 | 9:44 AM
RNV - Quarterly Investor Presentation
ReNerve Limited's Quarterly Investor Presentation outlines significant progress in their n
ReNerve Limited (RNV)
8 May 2026 | 10:02 AM

ReNerve Limited (RNV) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
ReNerve Limited (RNV)
ORDINARY FULLY PAID
 Health Care $11 Notification of cessation of securities - RNV 16 Jun 2026 9:02AM $0.084 $0.076 fallen by 9.52%
ReNerve Limited (RNV)
ORDINARY FULLY PAID
 Health Care $11 Clarification of Key Terms STC Distribution Agreement 16 Jun 2026 9:01AM $0.084 $0.076 fallen by 9.52%
ReNerve Limited (RNV)
ORDINARY FULLY PAID
 Health Care $11 ReNerve appoints J4 as second Empliq manufacturing partner 11 Jun 2026 9:47AM $0.077 $0.076 fallen by 1.30%
ReNerve Limited (RNV)
ORDINARY FULLY PAID
 Health Care $11 ReNerve appoints distribution partner for Malaysian Market 5 Jun 2026 9:15AM $0.077 $0.076 fallen by 1.30%
ReNerve Limited (RNV)
ORDINARY FULLY PAID
 Health Care $11 New distribution agreement for broader Hong Kong market 1 Jun 2026 9:44AM $0.080 $0.076 fallen by 5%
ReNerve Limited (RNV)
ORDINARY FULLY PAID
 Health Care $11 Quarterly Investor Presentation 8 May 2026 10:02AM $0.088 $0.076 fallen by 13.64%

RNV Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2025A -$3.73 -$3.00 44.30% 0.00 0.00 0.00% 0.0%
2024A -$2.98 -$2.10 65.40% 0.00 0.00 0.00% 0.0%
2023A -$1.80 -$1.30 2.40% 0.00 0.00 0.00% 0.0%

RNV Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2023 A 2024 A 2025 A 2023 A 2024 A 2025 A 2023 A 2024 A 2025 A
Ansell Limited (ANN) $4,384M 0.2270 0.0446 0.1434 16.2755 15.5801 13.6256 2.46% 2.91% 3.32%
Nanosonics Limited (NAN) $980M 0.5929 0.0000 0.0000 49.0284 0.0000 0.0000 0.00% 0.00% 0.00%
Polynovo Limited (PNV) $653M 1.5200 0.0000 0.0000 50.0000 0.0000 0.0000 0.00% 0.00% 0.00%
ReNerve Limited (RNV) $11M 0.4429 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%

RNV Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 2.08 0.00
Market 0.29 13.30 1.15 0.66
Sector 0.65 22.30 1.60 2.80

RNV Directors

Name Position Start Date
Dr Julian John Chick Chief Executive Officer, Executive Director 16 Sep 2016
Ms Maja Aleksandra McGuire Interim Chairman, Non-Executive Director 4 Dec 2025
Mr Paul Savage Non-Executive Director 4 Dec 2025

ReNerve Limited (RNV) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
25 Sep 2025 CHICK, Julian Buy Indirect Shares 300,000 $0.100 $30,000.000
25 Sep 2025 COOPER, Reginald Stephen Buy Indirect Shares 100,000 $0.100 $10,000.000
8 May 2025 COOPER, Reginald Stephen Buy Indirect Shares 194,915 $0.114 $22,190.650

See all changes in directors' interest & trades for ReNerve Limited (RNV) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

RNV Management

Name Position
David Lilja Chief Financial Officer,Company Secretary

RNV Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in ReNerve Limited (RNV). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
10,170,788 (7.14%) Zetland Road Pty Ltd
8,075,618 (5.67%) Ropehawn Investments Pty Ltd

RNV Calendar of Events

Date Event
25 February 2027 Report (Interim)
28 August 2026 Report (Annual)
28 August 2026 Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.